Blueprint Medicines Corporation logo
Blueprint Medicines Corporation BPMC

Quarterly report 2025-Q1
added 05-01-2025

report update icon

Blueprint Medicines Corporation Income Statement 2011-2026 | BPMC

Annual Income Statement Blueprint Medicines Corporation

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

5.96 B 5.31 B 2.66 B 6.27 B 6.12 B 3.07 B 3.11 B 3.06 B 913 M 287 M - - - -

Shares

62.9 M 60.6 M 59.6 M 58.5 M 54.5 M 47.8 M 43.9 M 37.8 M 27.5 M 18.2 M - - - -

Historical Prices

94.8 87.6 44.5 107 112 80.1 53.9 75.4 28.1 26.3 - - - -

Net Income

-67.1 M -507 M -558 M -644 M 314 M -348 M -237 M -148 M -72.5 M -52.8 M -40.3 M -20.9 M - -

Revenue

509 M 249 M 204 M 180 M 794 M 66.5 M 44.5 M 21.4 M 27.8 M 11.4 M - - - -

Cost of Revenue

20.2 M 8.54 M 17.8 M 17.9 M 425 K - - - - - - - - -

Interest Expense

656 K -946 K 2 M -1.49 M -366 K -100 K -180 K -76 K 551 K -429 K -98 K 226 K - -

EBITDA

16.3 M 11.7 M 11.7 M 6.48 M 6.56 M -356 M -243 M -150 M -71 M -50.7 M -39.2 M -20.3 M - -

Operating Expenses

- - - - - 428 M 292 M 173 M 100 M 63 M - - - -

General and Administrative Expenses

359 M 295 M 237 M 195 M 158 M 96.4 M 47.9 M 28 M 19.2 M 14.5 M 7.89 M 5.07 M - -

All numbers in USD currency

Quarterly Income Statement Blueprint Medicines Corporation

2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

64.1 M 63.7 M 63.4 M 62.9 M 61.6 M 61.1 M 60.7 M 60.5 M 60.1 M 60 M 59.8 M 59.6 M 59.3 M 59.1 M 58.6 M 58.4 M 58 M 57.8 M 55.2 M 54.2 M 52.7 M 49.3 M 48.9 M 48.8 M 44.1 M 44 M 43.9 M 43.9 M 43.7 M 43.6 M 39.1 M 38.8 M 33.2 M 33.1 M 27.3 M 27.2 M 27.1 M 27.1 M 26.8 M 17.1 M 1.68 M 1.63 M 1.45 M 1.37 M 1.28 M - - - - - - - - - - - -

Net Income

496 K - -56.3 M -50 M 89.1 M - -134 M -133 M -130 M - -133 M -160 M -106 M - -117 M -108 M -99.7 M - 634 M -123 M -111 M -66.3 M -94.3 M -99.7 M -87.4 M -80.3 M -72.7 M -27 M -56.5 M -49 M -37.7 M -33.4 M -28 M -21.3 M -16.8 M -18.9 M -15.5 M -15.6 M -12.6 M -13 M -11.6 M -14.5 M -10.5 M -8.29 M -7.03 M - - - - - - - - - - - -

Revenue

149 M - 128 M 138 M 96.1 M - 56.6 M 57.6 M 63.3 M - 66 M 36.5 M 62.7 M - 24.2 M 27.3 M 21.6 M - 745 M 8.34 M 6.17 M 51.5 M 9.14 M 5.11 M 730 K 1.03 M 1.1 M 41.4 M 954 K 1.63 M 8.07 M 5.89 M 5.84 M 7.69 M 6.16 M 7.06 M 6.86 M 4.64 M 3.43 M 2.69 M 652 K - - - - - - - - - - - - - - - -

Cost of Revenue

2.8 M - 1.93 M 7.59 M 3.19 M - 2.78 M 2.32 M 3.18 M - 3 M 4.89 M 5.08 M - 3.79 M 6.49 M 102 K - 146 K 127 K 24 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

461 K - 587 K -1 K 376 K - -728 K -626 K 986 K - 396 K 632 K -453 K - -522 K -373 K -214 K - -192 K -23 K -201 K - -72 K -42 K -44 K - 2.8 M 2.44 M 2.39 M - 954 K 861 K 425 K - 158 K 131 K 61 K - 6 K -405 K -37 K - -94 K 1 K 18 K - - - - - - - - - - - -

EBITDA

4.46 M - - - 4.81 M - - - 3.68 M - 4.72 M - 1.63 M - 4.82 M 1.6 M 1.61 M - 4.89 M 3.24 M 1.57 M - 3.68 M 2.39 M 1.18 M - 3.08 M 1.91 M 780 K - 1.19 M 791 K 398 K - 1.19 M 782 K 386 K - 615 K 411 K 209 K - 416 K 273 K 134 K - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - 121 M 107 M 109 M 90.8 M 84.2 M 76.6 M 70.9 M 59.9 M 51.7 M 46.7 M 40.1 M 34.2 M 29.1 M 23 M 26 M 22.3 M 20.1 M 15.9 M 15.1 M 12 M 14.3 M 10.3 M 8.2 M 6.95 M - - - - - - - - - - - -

General and Administrative Expenses

95.8 M - 89.9 M 89.3 M 83.6 M - 70.7 M 71.9 M 71 M - 57.6 M 58.7 M 57.1 M - 49.8 M 49.3 M 42 M - 37.4 M 42.2 M 35.7 M - 25.6 M 21.9 M 16.6 M - 12 M 12.3 M 9.91 M - 7.38 M 6.83 M 5.68 M - 4.89 M 4.69 M 4.65 M - 4.22 M 3.84 M 2.77 M - 1.92 M 1.44 M 1.57 M - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Blueprint Medicines Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 7.4 -2.25 % $ 200 M israelIsrael
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 15.11 0.6 % $ 6.16 B irlandaIrlanda
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Adagene Adagene
ADAG
$ 3.1 4.03 % $ 174 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.83 -1.14 % $ 4.53 M chinaChina
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.53 0.56 % $ 8.49 B australiaAustralia
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 221.49 - $ 5 B danmarkDanmark
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 59.93 -1.53 % $ 122 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 109.38 - $ 27.2 B germanyGermany
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.43 - $ 365 M britainBritain
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.7 - $ 4.54 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.13 - $ 1.49 B britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.27 -1.73 % $ 14.3 M usaUSA